MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
The study is a 2-part study of Tinodasertib alone or in combination with Pembrolizumab/Irinotecan in patients with CRC.
Metastatic Colorectal Cancer
DRUG: Tinodasertib|DRUG: Pembrolizumab|DRUG: Irinotecan
Adverse events and Serious Adverse events, Incidence and severity of AEs and SAEs., Approximately 2 years from date of participant enrolment|Incidence of DLT events and treatment emergent AEs (TEAEs), Grading of DLTs according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, 1 complete cycle (21 days)|Objective response rate based on Response Evaluation Criteria in Solid tumors (RECIST) Version 1.1, Approximately 2 years from date of participant enrolment
PK evaluation, Evaluation of Plasma concentrations of AUM001 as monotherapy or in combination with Pembrolizumab/Irinotecan, Approximately 6 months from date of participant enrolment
The study is conducted in 2 parts. First a dose escalation Run-in to identify the Maximum Tolerable Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Tinodasertib to be administered orally as monotherapy and in combination with intravenous pembrolizumab/irinotecan. Part 2 consists of a cohort expansion at the RP2D of Tinodasertib n combination with intravenous pembrolizumab/Irinotecan in patients with locally advanced or metastatic CRC to evaluate clinical activity and safety of Tinodasertib.